Collegium Pharmaceutical (COLL) announced its 2026 full-year financial guidance and provided a business update. Financial Guidance for 2026: Product revenues, net are expected in the range of $805 million to $825 million. Jornay PM net revenue is expected in the range of $190 million to $200 million. Adjusted EBITDA is expected in the range of $455 million to $475 million.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical price target raised to $55 from $47 at Truist
- Collegium Pharmaceutical Closes New $980 Million Credit Facility
- Collegium Pharmaceutical closes $980M syndicated credit facility
- Dyne Therapeutics appoints Vikram Karnani to board of directors
- Collegium Pharmaceutical initiated with an Overweight at Barclays